Ma2/Ta Antibody, IgG Serum
Test Mnemonic
MATA
CPT Codes
- 84182 - QTY (1)
Aliases
- Ma Paraneoplastic Syndrome
- PNM1/PNM2
- Ta Paraneoplastic Syndrome
- PNMA2
Includes
- Ma2/Ta Antibody, IgG by Immunoblot, Serum
Performing Laboratory
ARUP
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Serum | SST (Gold) | Refrigerated | Separate serum from cells ASAP or within 2 hours of collection and transfer to standard aliquot tube. |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.3 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Refrigerated | After separation from cells: 2 weeks |
| Ambient | After separation from cells: 48 hours |
| Frozen | After separation from cells: 1 month |
Days Performed
Mon, Thu, Sat
Turnaround Time
2 - 5 days
Methodology
| Name | Description |
|---|---|
| Immunoblot (IB), Qualitative |
Reference Range
Special Info
Contaminated, heat-inactivated, hemolyzed, or lipemic specimens will be rejected. This test is New York state approved.
Clinical Info
This test is useful in the diagnosis of autoimmune cerebellar ataxia and encephalitis. The presence of Ma2/Ta antibodies may be associated with cerebellar ataxia, encephalitis, dementia, and brainstem encephalitis. Ma2/Ta antibody disease may be paraneoplastic and is primarily associated with testicular cancer and adenocarcinoma. IgG antibodies to Ma2/Ta are associated with paraneoplastic neurologic syndromes with phenotypes most often including a combination of limbic encephalitis, diencephalic encephalitis, and brainstem encephalitis. Patients with anti-Ma2/Ta paraneoplastic neurologic syndromes should be thoroughly evaluated for cancer, including testicular cancer and adenocarcinoma, as neurologic symptoms often precede cancer diagnosis. Use of immune checkpoint inhibitors has also been associated with an increased risk of anti-Ma2 paraneoplastic neurologic disease. Consider sending testing in CSF as well as serum to improve diagnostic yield. Results (positive or negative) should be interpreted in the context of the patient's complete clinical picture, as false positives may occur, and a negative result does not exclude the diagnosis of paraneoplastic neurologic disease.